Weight loss medications are fundamentally reshaping how Americans treat obesity, with prescriptions for drugs like semaglutide and tirzepatide skyrocketing while bariatric surgery rates have fallen sharply since 2023. A major analysis of over 31 million patient records reveals that as access to these medications expanded, fewer people are choosing surgical intervention—a shift that experts say requires careful consideration about which treatment works best for whom. How Has the Obesity Treatment Landscape Changed? The transformation has been dramatic. Researchers analyzing national electronic health records found that prescriptions for semaglutide and tirzepatide—both glucagon-like peptide-1 (GLP-1) receptor agonists that help regulate appetite and blood sugar—increased more than 100-fold between the fourth quarter of 2018 and the third quarter of 2025, jumping from 0.22% to 24.17% of eligible patients. Meanwhile, metabolic and bariatric surgery (MBS), which includes procedures like gastric bypass and sleeve gastrectomy, peaked in late 2022 and then declined 46.4% over the next three years. This shift didn't happen overnight. Policy changes and drug approvals played major roles. When the American Medical Association declared obesity a chronic disease in 2013, antiobesity medication prescriptions began increasing at 0.31% per year. But the real acceleration came after semaglutide received approval for chronic weight management in 2021—prescriptions then jumped to increasing 1.42% annually. The approval of tirzepatide and other newer medications further accelerated the trend. Which Surgical Procedures Are Declining Most? Not all weight loss surgeries have declined equally. Sleeve gastrectomy—a procedure that removes about 80% of the stomach—experienced a steeper drop of 50.1% from mid-2022 to mid-2025, compared to a 44.3% decline in Roux-en-Y gastric bypass, which reroutes the small intestine to create a smaller pouch. Interestingly, the decline was least pronounced among patients with the highest body mass index (BMI) of 55 or greater, suggesting that surgery may still be preferred for the most severe cases of obesity. Why Are Doctors and Patients Choosing Medications Over Surgery? The appeal of GLP-1 medications is straightforward: they're less invasive than surgery, don't require hospitalization, and produce weight loss results that approach what surgery achieves. Patients can take a weekly injection rather than undergo an irreversible surgical procedure. Additionally, earlier access to these drugs—particularly for patients with type 2 diabetes—has made them a first-line treatment option before surgery is even considered. However, researchers emphasize that this shift raises important questions about treatment strategy. "Earlier access to GLP-1s in patients with diabetes and the observed decline in metabolic and bariatric surgery use irrespective of diabetes status, highlight complex decision-making regarding treatment," the study authors wrote. The concern is that some patients who might benefit most from surgery are now choosing medications instead. Steps to Understanding Your Weight Loss Treatment Options - Medication Route: GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing stomach emptying and signaling fullness to the brain. They require ongoing prescriptions and injections, typically weekly, and weight may return if you stop taking them. - Surgical Route: Metabolic and bariatric surgery, including sleeve gastrectomy and gastric bypass, permanently alters your digestive system. These procedures remain the most effective and durable treatment for severe obesity, particularly for those with a BMI of 40 or higher. - Combination Approach: Some patients may benefit from combining medications with lifestyle changes, or using medications as a bridge before considering surgery if needed. What Do Experts Say About This Treatment Shift? Medical professionals are watching this trend with cautious attention. The research shows that policy decisions and drug availability have enormous influence on treatment patterns—sometimes more than clinical evidence alone. When the AMA declared obesity a chronic disease in 2013, it legitimized medical treatment and increased prescriptions. But the introduction of semaglutide had an even larger impact, suggesting that availability and ease of use drive clinical decisions. Researchers stress that both approaches have a place in obesity care. "Developing evidence-based, patient-centered, multimodal pathways that integrate pharmacological and surgical approaches is essential because metabolic and bariatric surgery remains the most effective and durable treatment for severe obesity," the study authors emphasized. This means doctors should consider each patient's individual circumstances, severity of obesity, and long-term goals rather than defaulting to whichever option is most popular. Who Is Most Affected by This Shift? The data reveals important patterns by severity. Among patients with a BMI of 40 or higher (roughly 280 pounds for someone 5'10"), prescriptions for antiobesity medications increased substantially more after semaglutide's approval than they did for patients with lower BMIs. Yet bariatric surgery rates have declined across all BMI categories, including among those with the most severe obesity who historically relied on surgical intervention. This creates a potential gap: patients with the most severe obesity may be choosing medications when surgery could offer more lasting results. The study found that surgery use declined least among those with BMI of 55 or higher, suggesting some recognition that the most severe cases still need surgical options. What Does This Mean for the Future of Obesity Treatment? The 100-fold increase in GLP-1 prescriptions since 2018 represents a genuine revolution in how obesity is treated. These medications have made weight loss accessible to millions who previously had limited options. However, the sharp decline in bariatric surgery—down 46.4% in just three years—raises questions about whether the pendulum has swung too far in one direction. The key takeaway for patients is that obesity treatment is no longer one-size-fits-all. Your best option depends on your BMI, the severity of related health conditions like type 2 diabetes or sleep apnea, your ability to commit to ongoing medication, and your long-term goals. A conversation with your doctor about both pharmacological and surgical options—rather than assuming one is automatically better—is more important now than ever.
